KalshiVerfügbarkeit prüfenKYC erforderlichVerifizierte AuflösungsdatenGut kalibriertMittelwert des gewählten Orderbuchs
Above 8% · —
Gewähltes Orderbuch wird geladen…
—
Gespeicherter Preis
Above 8% 90%Führend unter 9 Optionen
Above 8% 90%Marktqualitat
30 / 100
Niedrige Qualität24h-Volumen
—
Open Interest
2413,1 $
Niedriges Open InterestGeld / Brief
— / —
Above 8%Spread
—
Marktdaten
Aktualisiert vor 37 Minuten
9. Sept. 26, 02:00 UTC31. März 27, 05:00 UTC
Chart und Änderungen zeigen gespeicherte historische Wahrscheinlichkeiten, nicht das gewählte aktuelle Orderbuch.
Trends
Gewählte Zeile: Orderbuch-Mittelwert. Andere Zeilen: gespeicherte, ggf. normalisierte Referenzwerte; 24h-Änderungen basieren auf gespeicherter Historie.
Handelsplatzbedingungen
Quelle: Kalshi
Diese Angaben dienen der Information; für den simulierten Handel bei CoinRithm gelten eigene Regeln.
- Vorzeitige Schließung:
- Ja
- Abrechnungsfrist:
- 30m (unverbindliche Angabe)
Markttiefe · Above 8%
Gewähltes Orderbuch wird geladen…
—
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Medtronic cardiovascular organic growth in fiscal 2027
KalshiWill 3 mg THC beverages be federally legal to sell?
KalshiWill Aurelia Song abandon Nectome before 2041?
Manifold MarketsWhich fast food chain in the USA will offer a lab-grown / cultivated meat product first?
Manifold MarketsWill an AI Labor Shock Crash Markets by 2035?
Manifold MarketsWhen will I be able to buy cultured meat at a random Whole Foods?
Manifold MarketsRegeln
If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Abwicklung über:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company. All trademarks, logos, and brand names are the property of their respective owners.
Regeln für jedes Ergebnis
- Above 8%
- If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 9%
- If Medtronic plc reports Above 9% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 10%
- If Medtronic plc reports Above 10% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 10.5%
- If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 11%
- If Medtronic plc reports Above 11% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 11.5%
- If Medtronic plc reports Above 11.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 12%
- If Medtronic plc reports Above 12% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 13%
- If Medtronic plc reports Above 13% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 14%
- If Medtronic plc reports Above 14% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
